Treat-and-extend AMD regimen sustains outcomes for up to 3 years

A treat-and-extend protocol improved vision and reduced retinal thickness for up to 3 years in patients with neovascular age-related macular degeneration, according to study findings.The retrospective study included 212 eyes of 189 patients with treatment-naïve neovascular AMD treated with Lucentis 0.5 mg/0.05 mL (ranibizumab, Genentech) or Avastin 1.25 mg/0.05 mL (bevacizumab, Genentech) for at least 1 year under a treat-and-extend regimen.